CAMP4 Therapeutics (NASDAQ:CAMP) Stock Rating Lowered by Zacks Research

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) was downgraded by investment analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other brokerages also recently commented on CAMP. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Rodman & Renshaw began coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They set a "buy" rating and a $7.00 target price for the company. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, June 10th. Weiss Ratings downgraded CAMP4 Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, May 21st. Finally, Leerink Partners boosted their target price on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an "outperform" rating in a research note on Thursday, April 2nd. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.36.

CAMP4 Therapeutics Stock Performance

Shares of CAMP stock opened at $3.90 on Wednesday. The stock's fifty day moving average is $4.28 and its two-hundred day moving average is $4.56. The firm has a market capitalization of $202.53 million, a P/E ratio of -1.65 and a beta of 0.10. CAMP4 Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.11). The business had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. On average, equities analysts forecast that CAMP4 Therapeutics will post -0.84 earnings per share for the current year.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vivo Capital LLC acquired a new stake in CAMP4 Therapeutics during the 3rd quarter worth approximately $11,765,000. Balyasny Asset Management L.P. acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth $14,938,000. Janus Henderson Group PLC lifted its stake in shares of CAMP4 Therapeutics by 35.9% in the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider's stock worth $38,807,000 after acquiring an additional 1,666,666 shares during the period. SummitTX Capital L.P. purchased a new stake in shares of CAMP4 Therapeutics in the first quarter valued at about $1,497,000. Finally, EcoR1 Capital LLC purchased a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at about $1,992,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.